Subject to the strictures of the regulatory process and the duty to consult, etc., yes.
On November 6th, 2018. See this statement in context.
On November 6th, 2018. See this statement in context.
November 6th, 2018 / 10:05 a.m.
Executive Director, Patented Medicine Prices Review Board
Subject to the strictures of the regulatory process and the duty to consult, etc., yes.
See context to find out what was said next.